3Rafols I, Hopkins M M, Hoekman J, et al. Big Pharma,little science? :A bibliometric perspective on Big Pharma's R&D decline[J]. Technol Forecast Soc Change,2012, doi: 10. 1016/j. techfore. 2012.06.007. http ://sciencedirect. corn/ science/article/pii/S0040162512001540 ? np=y. 被引量：1
4Adams C P, Brantner V V. Spending on new drug develop- mentl [ J]. Health Econ ,2010,19 (2) : 130-141. 被引量：1
5Munos B. Lessons from 60 years of pharmaceutical innova- tion[ J]. Nat Rev Drug D/scov,2009,8(12) :959-968. 被引量：1
6Light D W, Lexchin J R. Pharmaceutical research and development:what do we get for all that money? [ J ]. Br Med J,2012(345 ) :e4348. 被引量：1
7Schuhmacher A, Germann P G, Trill H, et al. Models for open innovation in the pharmaceutical industry [ J/OL ]. Drug Discov Today,2013, doi: 10. 1016/j. drudis. 2013. 07. 013. http://www, sciencedirect, corn/science/article/ pii/S135964461300247X. 被引量：1
8Gassmann O, Reepmeyer G, Von Zedtwitz M. Leading pharmaceutical innovation : trends and drivers for growth in the pharmaceutical industry [ M ]. Berlin : Springer, 2008. 被引量：1
9Wellenreuther R, Keppler D, Mumberg D,et al. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare [ J ]. Drug Discov Today,2012,17 (21) : 1242-1248. 被引量：1
10Correa C M. Towards a new model for pharmaceutical re- search[ J ]. Bull World Health Organ,2012(90 ) :795-795A. 被引量：1
